Two former LCRF grantees and a Scientific Advisory Board (SAB) member were among the co-authors of a study, “Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer,” published recently in Nature Cancer.

Dr. Ibiayi Dagogo-Jack
Dr. Aaron Hata
Satoshi Yoda
Dr. Satoshi Yoda

Satoshi Yoda, PhD, and Aaron Hata, MD, PhD both received grants from LCRF, and Ibiayi Dagogo-Jack, MD, was recently named as a member of LCRF’s SAB.